|
CCDC15 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6991963391888E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.20700013819908E-10 |
| Normal-vs-Stage2 |
9.64399671232741E-11 |
| Normal-vs-Stage3 |
3.21531690161692E-12 |
| Normal-vs-Stage4 |
7.21023241112562E-12 |
| Stage1-vs-Stage2 |
2.505800E-01 |
| Stage1-vs-Stage3 |
6.777600E-02 |
| Stage1-vs-Stage4 |
4.985800E-02 |
| Stage2-vs-Stage3 |
8.501200E-01 |
| Stage2-vs-Stage4 |
4.889800E-01 |
| Stage3-vs-Stage4 |
5.344200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.45800038708899E-11 |
| Normal-vs-AfricanAmerican |
2.85900000007722E-07 |
| Normal-vs-Asian |
2.241600E-04 |
| Caucasian-vs-AfricanAmerican |
4.069600E-01 |
| Caucasian-vs-Asian |
4.382400E-03 |
| AfricanAmerican-vs-Asian |
1.722240E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.24820154212557E-11 |
| Normal-vs-Female |
2.84110512893676E-11 |
| Male-vs-Female |
4.647600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.26210050691122E-10 |
| Normal-vs-Age(41-60Yrs) |
1.30100374917674E-11 |
| Normal-vs-Age(61-80Yrs) |
1.47389878080162E-11 |
| Normal-vs-Age(81-100Yrs) |
7.90110000000732E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.097200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.727600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.695810E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.127600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.774000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.834800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.089600E-01 |
| Classical-VS-Follicular |
2.026600E-01 |
| Classical-VS-Other |
7.244200E-01 |
| Classical-VS-Normal |
2.30459984429388E-10 |
| Tall-VS-Follicular |
7.763000E-01 |
| Tall-VS-Other |
6.248400E-01 |
| Tall-VS-Normal |
9.4605999700903E-09 |
| Follicular-VS-Other |
5.569000E-01 |
| Follicular-VS-Normal |
5.16789944171592E-11 |
| Other-VS-Normal |
2.721700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.10862446895044E-15 |
| Normal-vs-N1 |
1.35709998794198E-10 |
| N0-vs-N1 |
4.329000E-01 |
|
|
